Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
John T. Chang(University of California San Diego), Steven L. Reiner(Columbia University Irving Medical Center), Jane Oliaro(The University of Melbourne), Felix Schambach(The Wistar Institute), Sarah M. Russell(Peter MacCallum Cancer Centre), Andrew M. Intlekofer(Memorial Sloan Kettering Cancer Center), Arnob Banerjee(Johnson & Johnson (United States)), Jordan S. Orange(Children's Hospital of Philadelphia), Ichiko Kinjyo(The Wistar Institute), Wolfgang Weninger(Harvard University), V. Palanivel(The Wistar Institute), Kristine E. Vinup(The Wistar Institute), Paul Mrass(The Wistar Institute), Nigel Killeen(University of California, San Francisco), Sarah Longworth(The Wistar Institute)
Cited by 852
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Regulatory T Cells Reversibly Suppress Cytotoxic T Cell Function Independent of Effector Differentiation
|Immunity|2006|489
Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
|The Journal of Immunology|2010|417